Sulzberger Gabrielle
Eli Lilly and Co · Director
Sulzberger Gabrielle is listed in public filings as director. This Sulzberger Gabrielle insider trading page organizes Form 4 disclosures, reported purchases and sales, transaction dates, share amounts, related issuers, and historical insider activity so readers can review the person's public trading record in one place. Companies and tickers connected to this insider trading profile include Eli Lilly and Co (LLY), Mastercard Inc (MA), and Cerevel Therapeutics Holdings, Inc. (CERE). Investors use Sulzberger Gabrielle's insider trading disclosures to study buying and selling patterns, position changes, company-specific activity, and the source evidence behind each reported transaction.
Latest Actions
| Company | Holding Value | Last Transaction | Amount | Transaction Price | Current Price |
|---|---|---|---|---|---|
| $3.0M3k shares | Grant / ExerciseMay 18, 2026 | $5.0K5 shares | $988.09 | -- |
Insider Trades History
| Company | Holding Value | Last Transaction | Amount | Transaction Price | Current Price |
|---|---|---|---|---|---|
| $2.7M3k shares | Grant / ExerciseApr 20, 2026 | $5.0K5 shares | $919.90 | -- | |
| $2.9M3k shares | Grant / ExerciseMar 16, 2026 | $5.0K5 shares | $989.12 | -- | |
| $3.1M3k shares | Grant / ExerciseFeb 17, 2026 | $5.0K5 shares | $1,036.05 | -- | |
| $3.1M3k shares | Grant / ExerciseJan 20, 2026 | $5.0K5 shares | $1,041.29 | -- | |
| $3.1M3k shares | Grant / ExerciseDec 15, 2025 | $5.0K5 shares | $1,062.19 | -- | |
| $3.0M2.9k shares | Grant / ExerciseNov 17, 2025 | $220.0K215 shares | $1,021.70 | -- | |
| $2.8M2.7k shares | Grant / ExerciseNov 17, 2025 | $5.0K5 shares | $1,021.70 | -- | |
| --5.3k shares | Grant / ExerciseJun 24, 2025 | Disclosure amount unavailable458 shares | -- | -- | |
| $471k10.5k shares | OtherAug 1, 2024 | $2.2M48.4k shares | $45.00 | -- | |
| --10.5k shares | OtherAug 1, 2024 | Disclosure amount unavailable10.5k shares | -- | -- | |
| --95.2k shares | OtherAug 1, 2024 | Disclosure amount unavailable95.2k shares | -- | -- |